Chemistry and biodiversity p. 711 - 739 (2011)
Update date:2022-08-05
Topics:
Seebach, Dieter
Lukaszuk, Aneta
Patora-Komisarska, Krystyna
Podwysocka, Dominika
Gardiner, James
Ebert, Marc-Olivier
Reubi, Jean Claude
Cescato, Renzo
Waser, Beatrice
Gmeiner, Peter
Huebner, Harald
Rougeot, Catherine
The terminal homologation by CH2 insertion into the peptides mentioned in the title is described. This involves replacement of the N-terminal amino acid residue by a β2- and of the C-terminal amino acid residue by a β3-homo-amino acid moiety (β2hXaa and β3hXaa, resp.; Fig.1). In this way, the structure of the peptide chain from the N-terminal to the C-terminal stereogenic center is identical, and the modified peptide is protected against cleavage by exopeptidases (Figs.2 and 3). Neurotensin (NT; 1) and its C-terminal fragment NT(8-13) are ligands of the G-protein-coupled receptors (GPCR) NT1, NT2, NT3, and NT analogs are promising tools to be used in cancer diagnostics and therapy. The affinities of homologated NT analogs, 2b-2e, for NT1 and NT2 receptors were determined by using cell homogenates and tumor tissues (Table.1); in the latter experiments, the affinities for the NT1 receptor are more or less the same as those of NT (0.5-1.3 vs. 0.6nM). At the same time, one of the homologated NT analogs, 2c, survives in human plasma for 7 days at 37° (Fig.6). An NMR analysis of NT(8-13) (Tables.2 and 4, and Fig.8) reveals that this N-terminal NT fragment folds to a turn in CD3OH. - In the case of the human analgesic opiorphin (3a), a pentapeptide, and of the HIV-derived B27-KK10 (4a), a decapeptide, terminal homologation (→3b and 4b, resp.) led to a 7- and 70-fold half-life increase in plasma (Fig.9). With N-terminally homologated NPY, 5c, we were not able to determine serum stability; the peptide consisting of 36 amino acid residues is subject to cleavage by endopetidases. Three of the homologated compounds, 2b, 2c, and 5c, were shown to be agonists (Fig.7 and 11). A comparison of terminal homologation with other stability-increasing terminal modifications of peptides is performed (Fig.5), and possible applications of the neurotensin analogs, described herein, are discussed. Copyright
View MoreBeijing Zhongshuo Pharmaceutical T & D Co.,Ltd
Contact:0086-10-64430626
Address:ea No 16, HEPINGLI,DONGCHENG DISTRICT,BEIJING,P.R.CHINA.
Fujian Wanke Pharmaceutical Co., LTD.
Contact:+86-598-5026002
Address:Economic development zone,jiangle county
Jintan Jinnuo Chemical Co., Ltd.
Contact:+86-519-80199901
Address:Room 1804, Building 1, Huacheng Business Plaza, Jintan, Jiangsu, China
SHIJIAZHUANG HENRYTE CHEMICALS CO,.LTD
Contact:+86-311-85208698 311-80837698
Address:NO.166, yuhua west road, SHIJIAZHUANG, China
suzhou BetterBioChem Co., Ltd.
website:http://www.betterbiochem.com
Contact:+86-18013506594
Address:No. 8 Building, 18 nong, Xi Yingnan Road, Pudong, Shanghai,China
Doi:10.1021/jm200015a
(2011)Doi:10.1039/c1ob00008j
(2011)Doi:10.1021/ja01217a032
(1945)Doi:10.1016/S0040-4020(01)87367-1
(1986)Doi:10.1021/jo00371a024
(1986)Doi:10.1002/jhet.357
(2010)